Norden Group LLC Grows Holdings in Becton, Dickinson and Company (NYSE:BDX)

Norden Group LLC grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 2,086.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 51,934 shares of the medical instruments supplier’s stock after purchasing an additional 49,559 shares during the period. Norden Group LLC’s holdings in Becton, Dickinson and Company were worth $12,853,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth $761,798,000. Vanguard Group Inc. grew its position in shares of Becton, Dickinson and Company by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock worth $6,703,041,000 after buying an additional 516,427 shares in the last quarter. Royal Bank of Canada boosted its position in Becton, Dickinson and Company by 28.5% during the third quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock valued at $553,121,000 after purchasing an additional 473,914 shares in the last quarter. Morgan Stanley boosted its position in Becton, Dickinson and Company by 4.5% during the third quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after purchasing an additional 435,168 shares in the last quarter. Finally, Cooke & Bieler LP boosted its position in Becton, Dickinson and Company by 117.1% during the fourth quarter. Cooke & Bieler LP now owns 710,932 shares of the medical instruments supplier’s stock valued at $173,347,000 after purchasing an additional 383,485 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.2 %

Shares of NYSE:BDX opened at $228.84 on Thursday. Becton, Dickinson and Company has a 52-week low of $224.00 and a 52-week high of $287.32. The stock has a market cap of $66.14 billion, a price-to-earnings ratio of 50.41, a PEG ratio of 2.01 and a beta of 0.42. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average price of $234.16 and a 200-day moving average price of $237.71.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The firm had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same period last year, the business posted $2.86 earnings per share. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. Equities analysts predict that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Monday, June 10th were paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.66%. The ex-dividend date of this dividend was Monday, June 10th. Becton, Dickinson and Company’s payout ratio is 83.70%.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Roland Goette sold 3,300 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total value of $781,209.00. Following the transaction, the executive vice president now owns 11,308 shares of the company’s stock, valued at $2,676,942.84. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,615 shares of company stock worth $2,033,381. 0.31% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

BDX has been the topic of a number of recent research reports. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 price objective on the stock. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 27th. Barclays raised their price objective on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Finally, Evercore ISI lowered their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $280.86.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.